 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for CDKL4 |
 Gene summary |
| Basic gene information | Gene symbol | CDKL4 |
| Gene name | cyclin-dependent kinase-like 4 | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 2p22.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001009565.1, | |
| Description | - | |
| Modification date | 20141207 | |
| dbXrefs | HGNC : HGNC | |
| Ensembl : ENSG00000205111 | ||
| HPRD : 16698 | ||
| Vega : OTTHUMG00000133574 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CDKL4 | |
| BioGPS: 344387 | ||
| Pathway | NCI Pathway Interaction Database: CDKL4 | |
| KEGG: CDKL4 | ||
| REACTOME: CDKL4 | ||
| Pathway Commons: CDKL4 | ||
| Context | iHOP: CDKL4 | |
| ligand binding site mutation search in PubMed: CDKL4 | ||
| UCL Cancer Institute: CDKL4 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | HPA,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of CDKL4 | ||
| Description by TissGene annotations | Cancer gene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for CDKL4 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| Top |
| TissGene-miRNA for CDKL4 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for CDKL4 |
| TissGeneSNV for CDKL4 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.V106I | PAAD | 2 |
| p.L91M | PAAD | 1 |
| p.I119M | STAD | 1 |
| p.A148P | LUAD | 1 |
| p.S278F | HNSC | 1 |
| p.Q198P | STAD | 1 |
| p.Q112* | SKCM | 1 |
| p.Y211H | KIRC | 1 |
| p.R299H | HNSC | 1 |
| p.P240L | SARC | 1 |
| p.C143F | STAD | 1 |
| p.E241Q | LUAD | 1 |
| p.I142F | LUAD | 1 |
| p.E249Q | LUSC | 1 |
| p.R299H | LGG | 1 |
| p.R167X | READ | 1 |
| p.E301K | SKCM | 1 |
| p.M269I | HNSC | 1 |
| p.L133I | UCEC | 1 |
| p.G232R | SKCM | 1 |
| p.D254A | UCEC | 1 |
| p.Q309X | PAAD | 1 |
| p.V310L | LUAD | 1 |
| p.G302E | SKCM | 1 |
| p.P95Q | THYM | 1 |
| p.H85N | READ | 1 |
| p.N231K | LIHC | 1 |
| p.R223I | LUAD | 1 |
| p.E249Q | HNSC | 1 |
| p.H77N | ESCA | 1 |
| p.A31P | HNSC | 1 |
| p.L63V | BRCA | 1 |
| p.I52M | UCEC | 1 |
| p.M269V | UCEC | 1 |
| p.Q290* | SKCM | 1 |
| p.S181L | BRCA | 1 |
| p.Q290X | SKCM | 1 |
| p.Q309H | LUAD | 1 |
| p.V328L | KIRC | 1 |
| p.G174E | ESCA | 1 |
| p.G146E | SKCM | 1 |
| p.I103M | OV | 1 |
| p.D159N | SKCM | 1 |
| p.Q309* | PAAD | 1 |
| p.V106I | COAD | 1 |
| p.T247A | STAD | 1 |
| p.E193Q | STAD | 1 |
| Top |
| TissGeneCNV for CDKL4 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for CDKL4 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | BF885809 | CDKL4-SP3 | chr2:39431642 | chr2:174773462 |
| Top |
| TissGeneNet for CDKL4 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| Top |
| TissGeneProg for CDKL4 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for CDKL4 |
| TissGeneDrug for CDKL4 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for CDKL4 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0035372 | Rett Syndrome | 1 | GAD |
| umls:C0036572 | Seizures | 1 | GAD |
| umls:C0162635 | Angelman Syndrome | 1 | GAD |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |